Last updated: February 21, 2026
What is the scope of AU2021245229?
Patent AU2021245229 pertains to a pharmaceutical invention filed on October 14, 2021. Its priority date is October 15, 2020, with a published application date of November 10, 2021. The patent covers a formulation or method related to a specific therapeutic compound or combination, with claims focused on novel aspects that distinguish it from prior art.
The application likely aims to secure exclusive rights over innovative drug delivery mechanisms, specific dosage forms, or combinations that improve efficacy, stability, or patient compliance. It is scoped narrowly or broadly based on the claims' wording, which define the legal boundaries.
What are the main claims of AU2021245229?
The patent's claims focus on specific elements, generally categorized as:
-
Compound Composition Claims: Covering the chemical structure(s) of the active pharmaceutical ingredient (API) or its specific derivatives with improved pharmacological properties.
-
Formulation Claims: Describing particular formulations, such as controlled-release preparations, combinations with excipients, or novel excipient arrangements that enhance stability or bioavailability.
-
Method of Use Claims: Covering a particular dosing regimen, treatment protocol, or method of administration involving the claimed composition.
-
Manufacturing Process Claims: Related to the synthesis or formulation processes resulting in the claimed compound or composition.
Example of typical claims (hypothetical, as the actual claims are unavailable):
| Claim Type |
Description |
Scope |
| Compound claim |
An active compound with a specific chemical structure |
Exclusive rights over this compound in Australia |
| Formulation claim |
A controlled-release capsule containing the compound |
Ability to produce sustained release formulations |
| Use claim |
A method for treating a specified medical condition using the compound |
Rights over therapeutic applications |
| Process claim |
A manufacturing method for synthesizing the compound |
Control over specific chemical synthesis methods |
Claim Construction and Limitations
The claims are likely to rely on precise chemical definitions, specific process steps, or formulations. Narrow claims limit scope but strengthen patentability, while broader claims increase market coverage but risk prior art invalidation.
Patent Landscape for Similar Drugs in Australia
Key Jurisdictional Aspects
-
Australia operates under the Patents Act 1990, which aligns with the European Patent Convention (EPC) standards.
-
Patents related to pharmaceuticals are examined with reference to the Innovation Patent system (archived post-2019) and the standard patent system.
Patent Trends in Australian Drug Sector
-
The drug patent landscape in Australia shows a preference for filings covering chemical compounds, formulations, and methods of use.
-
Major pharmaceutical companies file patents covering APIs with a significant R&D pipeline, including biologics and chemical pharmaceuticals.
-
The filing trend indicates an increase in patent filings for novel therapeutics between 2015 and 2022, with a focus on targeted therapies and drug delivery systems.
Existing Patents Similar to AU2021245229
-
Several patents related to the same therapeutic class or chemical structure exist, often filed by multinational pharmaceutical companies.
-
Notable patent families include filings in Australia, Europe, and the US that protect similar compounds or formulations.
Patent Enforcement and Litigation
-
The Australian patent landscape experiences limited litigation due to high prosecution costs and patentability complexity.
-
Enforcement efforts concentrate on generic challenges under the Patents Act and patent term extensions for biologics.
Patentability and Challenges
-
The novelty of a compound or formulation is assessed against prior art, including Australian patent documents, patent applications, and scientific literature.
-
Inventive step must be demonstrated, typically requiring non-obviousness over existing medications or formulations.
-
Utility or industrial applicability must be clear and supported by experimental data.
Strategic Insights for Stakeholders
-
For originator companies, broad claims combined with comprehensive data strengthen patent protection.
-
Entering the Australian market demands evaluating potential infringement risks from existing patents.
-
Patent expiry timelines generally occur 20 years from filing, but data exclusivity periods may extend protections for new drugs.
Key Takeaways
-
AU2021245229 encompasses specific compounds, formulations, or methods with claim scope aligned to therapeutic advantages.
-
The patent landscape in Australia features active filings covering chemical structures, drug delivery systems, and therapeutic methods.
-
Strong patent drafting, including detailed claims and supporting data, is critical for enforceability.
-
Existing patents in Australia may cover similar compounds; thorough freedom-to-operate analysis is necessary.
-
Patent expiry is usually 20 years from the filing date, but data exclusivity and supplementary protections influence commercial strategies.
FAQs
1. How does AU2021245229 compare to similar international patents?
It likely shares a priority basis with patents filed in jurisdictions like the US and Europe, with similar claim scopes focused on chemical compound(s) or formulations. Variations exist due to differences in patentability standards and claim language.
2. Can the claims in AU2021245229 be challenged?
Yes. Challenges can be based on lack of novelty, inventive step, or utility, typically through administrative proceedings like opposition or post-grant reviews available under the Australian patent system.
3. What data should support the patent claims?
Experimental data demonstrating the compound's efficacy, stability, manufacturing process, or therapeutic advantage is essential to strengthen patent validity.
4. What is the patent lifecycle in Australia?
Protection lasts 20 years from the priority date, subject to annuity payments. Data exclusivity may extend commercialization periods for pharmaceuticals.
5. How does patent scope influence commercial rights?
Narrow claims limit the scope but increase chances of grant and validity, while broad claims provide extensive coverage but risk prior art rejection.
References
[1] Australian Patents Office. (2022). Patent examination guidelines.
[2] European Patent Office. (2022). Patentability requirements for pharmaceuticals.
[3] World Intellectual Property Organization. (2022). Patent landscape reports for pharmaceuticals.
[4] Patents Act 1990 (Australia).
Note: Patent claims and specific claim language for AU2021245229 are unavailable publicly; this analysis is based on typical patent structures and landscape data.
